股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 截至月份: 2025年4月30日 狀態: 新提交 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年5月9日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 9,500,000,000 | USD | 0.0001 | USD | | 950,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 9,500,000,000 | USD | 0.0001 | USD ...

Investment Rating - The report maintains a "Buy" rating for the company, with target prices unchanged for US, Hong Kong, and A-shares [3][13]. Core Insights - The company achieved a total revenue of $1.12 billion in Q1 2025, representing a year-over-year increase of 48.6% and a slight quarter-over-quarter decrease of 0.9% [4]. - The company reported a GAAP net profit of $1.27 million in Q1 2025, a significant improvement from a net loss of $251 million in Q1 2024 and $152 million in Q4 2024 [4]. - The company generated $44.08 million in operating cash flow in Q1 2025, marking its first quarter of achieving both GAAP operating profit and net profit ahead of market expectations [4]. - The company maintains its full-year guidance for 2025, projecting total revenue between $4.9 billion and $5.3 billion, with a gross margin expected to be in the range of 80%-90% [4]. Revenue and Sales Performance - Zebutinib sales reached $792 million in Q1 2025, up 62.1% year-over-year, with US sales contributing $563 million, a 60.2% increase year-over-year [5]. - The company reported a significant increase in sales across regions, with European sales at $116 million (up 73.5% YoY) and Chinese sales at $81.1 million (up 41.3% YoY) [5]. Profitability and Cost Management - The product gross margin was 85.1%, showing a notable increase from 83.3% in Q1 2024, driven by the growth in Zebutinib sales and improved production efficiency [6]. - Operating expenses grew only 6% year-over-year, with R&D expenses increasing by 5% to $480 million, indicating strong cost control [6]. Financial Projections - The report projects total revenue for 2025 to be $5.03 billion, with a year-over-year growth rate of 32.1% [14]. - The company is expected to achieve a net profit of $115 million in 2025, with projections for 2026 and 2027 remaining stable [13][14]. Pipeline and R&D Progress - The company is focusing on key pipeline products, with upcoming data releases expected from various clinical trials in 2025 [12]. - Notable upcoming events include the ASCO conference where initial human data for B7H4 ADC and CDK2 inhibitors will be presented [12].

Core Insights - BeiGene (ONC.O) reported a significant increase in total revenue for Q1 2025, reaching 8.048 billion yuan, a year-on-year growth of 50.2% [1] - The sales revenue from product sales was 7.985 billion yuan, reflecting a 49.9% increase compared to the previous year [1] Product Performance - The core product, Brukinsa (Zebutinib), achieved global sales of 5.692 billion yuan, marking a 63.7% increase year-on-year [1] - In the U.S. market, Brukinsa sales reached 4.041 billion yuan, up 61.9% year-on-year [1] - In Europe, sales amounted to 836 million yuan, a growth of 75.4% [1] - In China, sales were 590 million yuan, reflecting a 43.1% increase [1] - Another key product, Tislelizumab, generated sales of 1.245 billion yuan, with a year-on-year growth of 19.3% [1] - The growth of Tislelizumab was primarily driven by the inclusion of new indications in the medical insurance catalog in China and a significant increase in the number of hospitals carrying the drug [1] Financial Performance - BeiGene transitioned from a loss to profitability in Q1 2025, with adjusted operating profit of 1.171 billion yuan compared to an adjusted operating loss of 937 million yuan in the same period last year [1] - The adjusted net profit for the reporting period was 885 million yuan, a significant improvement from a net loss of 1.082 billion yuan in the previous year [1] Operational Efficiency - The overall performance improvement in Q1 2025 was attributed to substantial growth in product sales revenue and optimized expense management, which significantly enhanced the company's operational efficiency [2] - With the continued growth of core products and market expansion, BeiGene is expected to maintain a positive development trend in the future [2]

Core Viewpoint - BeiGene has shown significant improvement in reducing losses, with a notable increase in revenue driven by the sales of its self-developed products [1][2][3] Financial Performance - In Q1 2025, BeiGene reported revenue of 8.048 billion yuan, a year-on-year increase of 50.2%, marking the second consecutive quarter with revenue exceeding 8 billion yuan [1][2] - The net profit attributable to shareholders was -94.503 million yuan, a substantial reduction from -1.908 billion yuan in the same period last year, achieving a loss reduction rate of 95.05% [1][2] - For the full year 2024, the company reported revenue of 27.21 billion yuan, up 56.2% year-on-year, with a net profit loss reduced to 4.98 billion yuan [2] Product Performance - BeiGene has three major self-developed products: BTK inhibitor Zebrutinib (brand name "百悦泽"), PD-1 monoclonal antibody Tislelizumab (brand name "百泽安"), and PARP inhibitor Pamiparib (brand name "百汇泽") [3][4] - In Q1 2025, Zebrutinib generated global sales of 5.692 billion yuan, a 63.7% increase, accounting for 70.73% of total revenue [4] - Tislelizumab's sales reached 1.245 billion yuan in Q1 2025, a 19.3% increase, primarily due to new indications being included in the national medical insurance catalog in China [4] Research and Development Investment - BeiGene has invested heavily in R&D, with cumulative expenditures reaching approximately 69.788 billion yuan over the past eight years [5] - R&D expenses have consistently increased from 2.017 billion yuan in 2017 to 14.14 billion yuan in 2024, reflecting the company's commitment to innovation [5]

Core Insights - The article emphasizes the importance of patient investing and the accumulation of high-quality assets over time as a key to wealth creation [1] - It highlights the balance between steady investment strategies and high-risk, high-reward opportunities as essential for enjoying the investment process [1] - The author advocates for investing in companies and industries that contribute positively to society [1] Investment Philosophy - The investment approach focuses on the joy of compounding and the value of dividend reinvesting [1] - The principle of investing through both good and bad times is presented as a strategy that yields the greatest rewards [1] - The author identifies a mix of steady investments and transformative technologies as a way to enhance investment returns [1] Personal Background - The author describes themselves as an amateur investor with no formal education in investing or business, emphasizing self-education and learning from others [1] - The author holds a PhD from Brunel University and has experience teaching at the college/university level [1]

Core Insights - BeiGene reported a revenue of 8.048 billion yuan for Q1 2025, marking a year-on-year increase of 50.2% [1] - The company's product revenue reached 7.985 billion yuan, up 49.9% year-on-year, leading to a significant reduction in losses to 0.095 billion yuan from 1.908 billion yuan in the same period last year [1] - The growth in product revenue was primarily driven by its core self-developed products, Brukinsa® (Zebutinib) and Tislelizumab, as well as sales growth from Amgen's licensed products [1] Revenue Breakdown - Brukinsa® achieved global sales of 5.692 billion yuan in Q1 2024, reflecting a 63.7% increase year-on-year [1] - In the U.S. market, Brukinsa® sales reached 4.041 billion yuan, up 61.9% year-on-year, while in China, sales were 0.590 billion yuan, a 43.1% increase [1] - Brukinsa® is now approved in 75 markets globally, with 11 markets adding or expanding reimbursement coverage in the quarter [1] PD-1 Product Performance - Tislelizumab generated sales of 1.245 billion yuan in Q1 2025, a year-on-year increase of 19.3%, attributed to new indications approved for reimbursement in China and increased hospital access [2] - Tislelizumab is approved for 14 indications in China, with 13 of those included in the national reimbursement list [2] - Despite the strong sales figure, the growth rate for Tislelizumab has slowed compared to the previous year's 32.8% [2] Global Market Expansion - The overseas market has become a significant driver of BeiGene's performance growth, with Tislelizumab recently approved in Japan and Indonesia [2] - Tislelizumab is now approved in 46 markets globally, with over 1.5 million patients treated [2] - In Q1 2025, Tislelizumab was added to the reimbursement list in 11 new markets, including the U.S., Europe, and China [2] Corporate Developments - BeiGene will adopt a new English name, BeOne Medicines Ltd., while retaining its Chinese name, and will relocate its registration to Switzerland, expected to be completed later this year [2]

【环球网财经综合报道】2024年A股上市公司年报收官，董事长薪酬榜单引发市场关注。根据Wind数据统计，4231家上市公司披露了董事长年度薪酬，合计 金额达57.89亿元。其中，13位董事长年薪超过1000万元，主要来自医药生物、电子、家用电器、食品饮料、传媒、基础化工等行业。 药明康德董事长李革以4180万元年薪位居榜首，成为A股"薪酬之王"，迈瑞医疗董事长李西廷以2493.9万元紧随其后，百济神州董事长欧雷强则以2019.38万 元位列第三。这三大巨头均来自生物医药行业，再度印证了该领域"高附加值、高成长性"的造富逻辑。 A股董事长薪酬分布呈橄榄型，其中年薪在100万元至200万元的人数最多，达1402人，占比约三分之一。年薪超500万元但不足1000万元的董事长有79人， 而年薪低于40万元的则有385人。总体来看，年薪超百万的董事长有2093人，与年薪低于百万的人数相当，各占半壁江山。 薪酬榜单也凸显了行业间的"冰火两重天"。传媒、电子、医药生物等行业董事长平均薪酬较高，而房地产、证券等行业则普遍降薪。例如，传媒行业董事长 平均年薪178万元，位列各行业之首；电子行业平均年薪175万元；医药生物和美容 ...

Summary of the Conference Call for BeiGene's Q1 2025 Performance Company Overview - **Company**: BeiGene - **Industry**: Biotechnology and Pharmaceuticals Key Financial Highlights - **Q1 2025 Revenue**: $1.12 billion, an increase of 48.6% year-over-year [1] - **Product Revenue**: $1.11 billion [1] - **Net Profit**: $1.27 million, a turnaround from a net loss of $250 million in the same period last year [1][3] - **Gross Margin**: 85.2%, up by 1.9 percentage points [2] - **R&D Expenses**: $480 million, an increase of 4.6%, with an R&D expense ratio of 43.1%, down by 18.2 percentage points [2] - **SG&A Expenses**: $460 million, an increase of 7.5%, with an SG&A expense ratio of 41.1%, down by 15.8 percentage points [2] Product Performance - **Zebutinib**: - Revenue: $790 million, up 62.1% year-over-year, but down 4.4% quarter-over-quarter [1][2] - Sales Breakdown: - **United States**: $560 million, up 60.2% [2] - **Europe**: $120 million, up 73.4% [2] - **China**: $80 million, up 41.3% [2] - **Other Regions**: $30 million, up 145.4% [2] - The slight quarter-over-quarter decline attributed to channel inventory adjustments due to high shipments in Q4 2024, with expectations for continued growth in Q2 2025 [2] - **Tislelizumab**: Revenue of $170 million, an increase of 17.8% [2] - **Collaborative Products in China**: Revenue of $110 million, up 58.7%, primarily driven by the growth of Duzallo [2] Future Catalysts - Upcoming catalysts for 2025 include: - **Sonrotoclax (BCL2)**: Phase II data readout for R/R MCL and submission for global accelerated approval in 2H 2025 [3] - **BGB-43395 (CDK4)**: Proof of Concept data readout in 1H 2025 [3] - **BGB-16673 (BTK CDAC)**: Initiation of treatment for R/R CLL and head-to-head Phase III trial with Eli Lilly's third-generation BTK inhibitor in 2H 2025 [3] Management Guidance - Management maintains the full-year revenue guidance of $4.9 billion to $5.3 billion unchanged [1][2]

Summary of the Conference Call for BeiGene (1Q25) Company Overview - **Company**: BeiGene - **Industry**: Biotechnology/Pharmaceuticals Key Financial Performance - **1Q25 Revenue**: - Net product sales reached **$1.109 billion**, representing a **48% year-over-year increase** [1] - **Zebutinib Global Sales**: **$792 million**, with a **62% year-over-year increase** [1] - **U.S. Sales**: **$563 million**, up **60% year-over-year** [1] - **European Sales**: **$116 million**, up **73% year-over-year** [1] - **Tislelizumab Sales**: **$171 million**, reflecting an **18% year-over-year increase** [1] - **GAAP Net Profit**: Achieved a net profit of **$1.27 million**, marking the first quarterly profit [1] Strategic Developments - **Investor R&D Day**: Scheduled for **June 26**, focusing on breast cancer and other solid tumor pipelines [1] - **Reimbursement Expansion**: Zebutinib has been included or expanded in reimbursement in **11 markets**, including Japan, Europe, and Brazil [1] - **New Supplier**: Engaged **Siegfried** as a new supplier for active pharmaceutical ingredients for Zebutinib [1] - **Regulatory Filings**: BCL2 has been submitted for approval in China for the treatment of R/R CLL [1] - **Clinical Trials**: - Initiated a Phase III clinical trial for BTKCDAC in treating R/R CLL, comparing against physician's choice of treatment [1] - DLL3/CD3 bispecific antibody (in collaboration with Amgen) reported positive data from the Phase III trial for 2L SCLC [1] - CDK4 is expected to report Proof of Concept data in the first half of 2025 [1] Additional Insights - The significant growth in Zebutinib sales is attributed to its increasing market share in the treatment of new CLL patients, positioning it as the top seller in the U.S. BTK market [1]

Market Overview - US stock markets collectively rose, with the Dow Jones up 0.7%, Nasdaq up 0.27%, and S&P 500 up 0.43% [1] - Nvidia increased by 3.1%, Amazon by 2%, and Meta Platforms by 1.62%, while Google A dropped by 7.26% [1] Federal Reserve - The Federal Reserve maintained the federal funds rate target range at 4.25%-4.5%, aligning with market expectations [2] Technology Developments - Trump plans to abolish AI chip restrictions imposed during Biden's administration [3] - Apple is preparing a major overhaul of Safari, targeting AI search capabilities, which poses a significant challenge to Google's market position [6] - OpenAI is in discussions with the FDA to incorporate AI in drug evaluation processes [7] - OpenAI plans to expand its "Stargate" project beyond the US [5] Defense Spending - Germany's Defense Minister aims to increase annual defense spending to over €60 billion starting in 2025 [4] Investment Activities - Uber is committing an additional $100 million equity investment in WeRide [8] Domestic Developments - The Chinese government is enhancing financial support for small and micro enterprises in sectors like accommodation, catering, and tourism [9] - The China Securities Regulatory Commission has issued a plan to promote high-quality development of public funds, linking fund manager compensation to performance [9] Market Strategies - Everbright Securities indicates signs of improvement in tariff issues and anticipates more favorable domestic policies, suggesting a potential upward trend in the market [10] - Huawei is set to launch its HarmonyOS-based PC, marking a significant entry into the desktop operating system market [10] - XPeng Motors is considering an IPO for its flying car subsidiary, XPeng Heavens, potentially in Hong Kong or the US [10][11] Robotics and AI - Lenovo has launched the first personal and enterprise "super intelligent agent" at the TechWorld conference [12] - The world humanoid robot competition will take place in Beijing in August 2025, marking a significant event in the robotics industry [13] Company Announcements - Hainan Development plans to acquire a 51% stake in Wangying Technology for ¥450 million [16] - Qingdao Beer intends to acquire 100% of Jimo Yellow Wine to enhance product lines and market channels [16] - Xinjian Mining's acquisition of Xinjiang Meisheng Mining is aimed at expanding its resource base [16] - Baijia Shenzhou reported a turnaround from loss to profit in Q1, driven by sales growth of its self-developed products [17] Stock Performance - Notable stock performances include Tongyi Aerospace up 25.11%, Changshan Pharmaceutical up 20.02%, and Huawei Harmony up 14.01% [18] Upcoming Market Events - Several companies will have their shares unlocked, including Guotai Haitong with a market value of ¥4.83 billion on May 8 [19][20]